News InflaRx stock halves after it drops lead drug InflaRx has abandoned its drug development programme, vilobelimab for rare skin disease pyoderma gangrenosum, cratering its share price.
News UK biotech investment "holding firm", says BIA The UK life sciences raised £1.23bn in venture capital investment in the first half of 2025, although there was a fallback in the second quarter.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face